Applying even stricter criteria, Taechasan and Jiamjarasrangsi (2024) excluded participants with abnormal liver function tests, such as elevated Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), lipid accumulation product (LAP), or hepatic steatosis index (HSI), ensuring that only incident NAFLD cases were included in the analysis. The gene discussed is GPT; the disease is fatty liver disease.